Inhibition of acetylcholinesterase activity and β‑amyloid oligomer formation by 6‑bromotryptamine A, a multi‑target anti‑Alzheimer's molecule

  • Authors:
    • Xiaofeng Jin
    • Minjun Wang
    • Jieyi Shentu
    • Chunhui Huang
    • Yujing Bai
    • Hanbo Pan
    • Difan Zhang
    • Zhijun Yuan
    • Hui Zhang
    • Xiao Xiao
    • Xiang Wu
    • Lijian Ding
    • Qinwen Wang
    • Shan He
    • Wei Cui
  • View Affiliations

  • Published online on: December 18, 2019     https://doi.org/10.3892/ol.2019.11226
  • Pages: 1593-1601
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by learning and memory impairments. Recent studies have suggested that AD can be induced by multiple factors, such as cholinergic system dysfunction and β‑amyloid (Aβ) neurotoxicity. It was reported that 6‑bromo‑N‑propionyltryptamine could treat neurological diseases, including AD. In the present study, 6‑bromotryptamine A, a derivative of 6‑bromo‑N‑propionyltryptamine, was synthesized by the condensation of 2‑(6‑bromo‑1H‑indol‑3‑yl)ethan‑1‑amine and 2‑(4‑bromophenyl)acetic acid, and was used as a potential anti‑AD molecule. Furthermore, scopolamine can induce impairments of learning and memory, and was widely used to establish AD animal models. The results demonstrated that 6‑bromotryptamine A significantly prevented scopolamine‑induced short‑term cognitive impairments, as revealed by various behavioral tests in mice. Furthermore, an acetylcholinesterase (AChE) activity assay revealed that 6‑bromotryptamine A directly inhibited AChE activity. Notably, it was observed that 6‑bromotryptamine A blocked the formation of Aβ oligomer, as evaluated by the dot blot assay. All these results suggested that 6‑bromotryptamine A may be used to prevent impairments in short‑term learning and memory ability possibly via the inhibition of AChE and the blockade of Aβ oligomer formation.
View Figures
View References

Related Articles

Journal Cover

February-2020
Volume 19 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jin X, Wang M, Shentu J, Huang C, Bai Y, Pan H, Zhang D, Yuan Z, Zhang H, Xiao X, Xiao X, et al: Inhibition of acetylcholinesterase activity and β‑amyloid oligomer formation by 6‑bromotryptamine A, a multi‑target anti‑Alzheimer's molecule. Oncol Lett 19: 1593-1601, 2020.
APA
Jin, X., Wang, M., Shentu, J., Huang, C., Bai, Y., Pan, H. ... Cui, W. (2020). Inhibition of acetylcholinesterase activity and β‑amyloid oligomer formation by 6‑bromotryptamine A, a multi‑target anti‑Alzheimer's molecule. Oncology Letters, 19, 1593-1601. https://doi.org/10.3892/ol.2019.11226
MLA
Jin, X., Wang, M., Shentu, J., Huang, C., Bai, Y., Pan, H., Zhang, D., Yuan, Z., Zhang, H., Xiao, X., Wu, X., Ding, L., Wang, Q., He, S., Cui, W."Inhibition of acetylcholinesterase activity and β‑amyloid oligomer formation by 6‑bromotryptamine A, a multi‑target anti‑Alzheimer's molecule". Oncology Letters 19.2 (2020): 1593-1601.
Chicago
Jin, X., Wang, M., Shentu, J., Huang, C., Bai, Y., Pan, H., Zhang, D., Yuan, Z., Zhang, H., Xiao, X., Wu, X., Ding, L., Wang, Q., He, S., Cui, W."Inhibition of acetylcholinesterase activity and β‑amyloid oligomer formation by 6‑bromotryptamine A, a multi‑target anti‑Alzheimer's molecule". Oncology Letters 19, no. 2 (2020): 1593-1601. https://doi.org/10.3892/ol.2019.11226